{"id":"NCT00406367","sponsor":"Merz Pharmaceuticals GmbH","briefTitle":"IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Blepharospasm","officialTitle":"Prospective, Double-blind, Placebo-controlled, Randomized, Multi-center Trial With an Open-label Extension Period to Investigate the Efficacy and Safety of incobotulinumtoxinA (Xeomin) in the Treatment of Blepharospasm","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-10","primaryCompletion":"2008-04","completion":"2009-07","firstPosted":"2006-12-04","resultsPosted":"2010-11-16","lastUpdate":"2013-03-15"},"enrollment":109,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Blepharospasm"],"interventions":[{"type":"DRUG","name":"incobotulinumtoxinA (Xeomin)","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"incobotulinumtoxinA (Xeomin)","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Patients received one injection with incobotulinumtoxinA (Xeomin) or placebo at baseline. Thereafter, all patients who entered the Open-Label Extension Period (OLEX) received up to five injection sessions of incobotulinumtoxinA (Xeomin) during the OLEX period.","primaryOutcome":{"measure":"Jankovic Rating Scale (JRS) Change From Baseline in the JRS Severity Subscore at Week 6 After Injection (Assessed by a Blinded Independent Rater)","timeFrame":"Baseline, week 6","effectByArm":[{"arm":"incobotulinumtoxinA (Xeomin)","deltaMin":-0.8,"sd":0.13},{"arm":"Placebo","deltaMin":0.2,"sd":0.18}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":7},"locations":{"siteCount":2,"countries":["United States","Canada"]},"refs":{"pmids":["21520284","23435927"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":74},"commonTop":["Dry eye","Eyelid ptosis","Dry mouth","Headache","Diarrhoea"]}}